Resistant Cancer clinical trials at UCSF

• 9-ING-41 in Patients With Advanced Cancers

  open to eligible people ages 18 years and up

  GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

  San Francisco, California and other locations

Last updated: April 9, 2020